XZXiangsheng Zuo

Xiangsheng Zuo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xiangsheng Zuo has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: New advancement in tumor microenvironment remodeling and cancer therapy, volume II

    by Sumei Qin, Xiaoxiong Xiao, Ying Shen, Zhihua Pei, Xiangsheng Zuo, Yi Yao

    The tumor microenvironment (TME) is a complex ecosystem composed of diverse cellular components (including fibroblasts, immune cells, and endothelial cells) and non-cellular elements (such as extracellular matrix and cytokines). Although traditionally considered a passive bystander in tumorigenesis, the TME is now recognized as a central driver of tumor progression, metastasis, immune evasion, and therapeutic resistance. This paradigm shift-from "bystander" to "participant" and further to "regulator"-marks a new era in tumor biology (Grant and Ferrer, 2025). Understanding TME remodeling mechanisms not only provides novel insights into malignant tumor behavior but also opens broad horizons for developing innovative therapeutic strategies that move beyond the traditional tumor-centric view.Recent studies have dissected the heterogeneity of cancer-associated fibroblasts (CAFs) at an unprecedented resolution, identifying functionally distinct subsets such as myofibroblastic CAFs (myCAFs) and inflammatory CAFs (iCAFs). These subsets play different, and even opposing, roles in tumor progression and can serve as biomarkers for predicting prognosis and immunotherapy response (Cords et al., 2024). For instance, Chen et al. identified a PRRX2+ myCAF subset that promotes perineural invasion via TGF-β signaling in colorectal cancer, closely correlating with poor prognosis. Similarly, Damisch et al. revealed fibromuscular cell heterogeneity in prostate cancer stroma with clinical correlates. Notably, driven by advances in single-cell sequencing and spatial omics technologies, an increasing number of novel CAF subsets have been identified. For example, a chemotherapy-induced PTGER3 + lipoCAF subset has been shown to produce the lipid metabolite 11-HETE, thereby enhancing CD8 + T cell function (Ma et al., 2026).The mechanisms underlying dynamic immune microenvironment remodeling are becoming increasingly clear. Tumor cells establish a potent immunosuppressive network through chemokine secretion, immune checkpoint molecule expression, and metabolic reprogramming, recruiting regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and inducing M2 polarization of tumor-associated macrophages (TAMs) (Zhang et al., 2025). In addition to tumor cell-intrinsic drivers, chemotherapeutic intervention is capable of profoundly reshaping the immune microenvironment. Gemcitabine, for instance, is not merely a conventional cytotoxic chemotherapeutic agent, but also exhibits immunomodulatory properties that may potentiate antitumor immune responses when combined with immune checkpoint inhibitors (Principe et al., 2020;Ho et al., 2020). However, subsequent studies have shown that this immunomodulation is not unidirectional. As reviewed by Nemati et al., gemcitabine exhibits dual immunomodulatory roles, activating immunity via immunogenic cell death while potentially promoting M2 polarization or MDSC accumulation, highlighting the complex interplay between therapy and TME. Collectively, these effects of gemcitabine reveal the plasticity of TME and highlight the potential of immunotherapy strategies in regulating the TME.Beyond cellular components, metabolic and physical factors within the TME are also research hotspots. Hypoxia, a hallmark of most solid tumors, drives hypoxia-inducible factor (HIF) signaling that promotes angiogenesis and reprograms metabolism, exacerbating immunosuppression. Wang et al. found that overexpression of VWF, a malignant gene in tumor-associated endothelial cells, drives hypoxic metabolism in gastric cancer and fosters an immunosuppressive microenvironment, thereby diminishing the efficacy of immunotherapy. Hou et al. demonstrated that insufficient radiofrequency ablation (IRFA) for hepatocellular carcinoma promotes malignant progression of residual tumors through local inflammation, hypoxia, non-coding RNA dysregulation, and autophagy. Additionally, Chen et al. uncovered disulfidptosis, a novel cell death triggered by glucose starvation in SLC7A11-high ovarian cancer cells, offering new strategies for targeting metabolic vulnerabilities in the TME.Emerging frontiers further enrich our understanding of TME complexity. Spatial transcriptomics has revealed that TME composition varies drastically between tumor core and invasive front, with distinct CAF and immune cell distributions that influence therapeutic response (Ji et al., 2025). Spatial multi-omics analyses of the cellular neighborhood of CAFs have further identified distinct spatial CAF subtypes characterized by unique organization, expression profiles, and interactions. These subtypes are conserved across cancer types and associate with distinct TME features and clinical outcomes, underscoring that CAF phenotypes and functions are shaped by neighboring cell interactions (Liu et al., 2025). Additionally, the senescence-associated secretory phenotype (SASP) derived from senescent stromal cells can paradoxically promote tumor progression and immunesuppression (Cao et al., 2025). Recent studies also highlight that intratumoral microbiota modulate local immune landscapes and impact the response to immune checkpoint inhibitors, further complicating therapeutic strategies (Yan et al., 2026). Furthermore, the establishment of nextgeneration high-throughput technology platforms has provided novel tools for the spatial dissection of the TME, revealing how the loss of various tumor suppressor genes shapes the TME and contributes to immunotherapy resistance (Wang et al., 2026). Collectively, these advances underscore the need for multi-dimensional approaches to dissect TME complexity (Larson et al., 2025). Despite these advances, several challenges remain. The foremost challenge is the extreme spatial and temporal heterogeneity of the TME, which makes it difficult for studies based on limited markers to capture the full picture. Our understanding of the dynamic processes governing TME remodeling during tumorigenesis,...

  • PPARδ: An underappreciated tumor accelerator in pancreatic ductal adenocarcinoma

    by Danping Niu, Daoyan Wei, Yi Liu, James C. Yao, Imad Shureiqi, Xiangsheng Zuo

  • CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer

    by Daoyan Wei, Liang Wang, Yi Liu, Xiangsheng Zuo, Xiling Shen, Robert S. Bresalier

    Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies, characterized by late diagnosis, early metastasis, and resistance to conventional therapies. A major barrier to effective treatment is its desmoplastic and immunosuppressive tumor microenvironment, which restricts T-cell infiltration and dampens responses to immune checkpoint inhibitors (ICI). These features highlight the urgent need for innovative immunotherapeutic strategies capable of overcoming PDAC’s immunologic and physical barriers. Chimeric antigen receptor (CAR)-macrophage (CAR-M) therapy has emerged as a promising approach to address these challenges. Unlike CAR-T or CAR-NK cells, CAR-Ms can efficiently infiltrate tumors, remodel the tumor microenvironment, phagocytose tumor cells, and stimulate adaptive immunity. This review highlights recent advances in CAR-M therapy for solid tumors, with an emphasis on PDAC. Preclinical studies show that CAR-Ms enhance antigen presentation, secrete proinflammatory cytokines, and recruit cytotoxic T cells, thereby amplifying antitumor responses. Progress in CAR-M engineering—such as dual-targeting strategies, CRISPR-based modifications, and combinations with ICIs or other therapies—further strengthens their therapeutic potential. Importantly, early-phase clinical trials in solid tumors support the safety, tolerability, and tumor-modulating capacity of CAR-Ms, laying the groundwork for their application in PDAC. To fully harness CAR-M therapy in PDAC, several challenges must be addressed, including improving CAR-M persistence and efficacy, optimizing tumor-specific targeting, developing scalable and cost-effective manufacturing platforms, and integrating strategic combinations with other therapies, such as ICIs and KRAS inhibitors. With continued innovation and clinical validation, CAR-M therapy has the potential to transform PDAC treatment, fulfill critical unmet clinical needs, and provide new hope for patients.


  • Open Access

    Colorectal ALOX15 as a host factor determinant of EPA and DHA effects on colorectal carcinogenesis

    by Xiangsheng Zuo, Yoshiyuki Kiyasu, Yi Liu, Yasunori Deguchi, Fuyao Liu, Micheline Moussalli, Lin Tan, Bo Wei, Daoyan Wei, Peiying Yang, et al.

    Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), omega-3 polyunsaturated fatty acids (ω-3 PUFAs) derived from fish oil, are widely used as dietary supplements and FDA-approved treatments for hypertriglyceridemia. However, studies investigating the effects of EPA and DHA on colorectal carcinogenesis (CRC) have yielded conflicting results. The factors that determine these discrepant results remain unknown. Resolvins, oxidative metabolites of EPA and DHA, inhibit key pro-tumorigenic cytokine and chemokine signaling of colorectal cancer (e.g., IL-6, IL-1β, and CCL2). 15-lipoxygenase-1 (ALOX15), a critical enzyme for resolvin generation is commonly lost during human CRC. Whether ALOX15 expression, as a host factor, modulates the effects of EPA and DHA on CRC remains unknown. Therefore, we evaluated the effects of ALOX15 transgenic expression in colonic epithelial cells on resolvin generation by EPA and DHA and CRC in mouse models representative of human CRC. Our results revealed that 1) EPA and DHA effects on CRC were diverse, ranging from suppressive to promotive, and these effects were occasionally altered by the formulations of EPA and DHA (free fatty acid, ethyl ester, triglyceride); 2) EPA and DHA uniformly suppressed CRC in the presence of intestinal ALOX15 transgenic expression, which induced the production of resolvins, decreased colonic CCL3-5 and CXCL-5 expression and tumor associated macrophages while increasing CD8 T cell abundance in tumor microenvironment; and 3) RvD5, the predominant resolvin produced by ALOX15, inhibited macrophage generation of pro-tumorigenic cytokines. These findings demonstrate the significance of intestinal ALOX15 expression as a host factor in determining the effects of EPA and DHA on CRC. Significance Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are widely used as dietary supplements and FDA-approved treatments for hypertriglyceridemia. Studies of EPA and DHA effects on colorectal carcinogenesis (CRC) have revealed inconsistencies; factors determining the direction of their impact on CRC have remained unidentified. Our data show that EPA and DHA effects on CRC were divergent and occasionally influenced by their formulations. More importantly, intestinal 15-lipoxgenase-1 (ALOX15) expression modulated EPA and DHA effects on CRC, leading to their consistent suppression of CRC. ALOX15 promoted EPA and DHA oxidative metabolism to generate resolvins, which inhibited key pro-tumorigenic inflammatory cytokines and chemokines, including IL-6. IL-1β, and CCL2. ALOX15 is therefore an important host factor in determining EPA and DHA effects on CRC.

  • Open Access

    Editorial: New advancement in tumor microenvironment remodeling and cancer therapy

    by Yi Yao, Ying Shen, James C. Yao, Xiangsheng Zuo

    Editorial: New advancement in tumor microenvironment remodeling and cancer therapy


  • Top Cited Papers

    A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer

    by Daoyan Wei, Liang Wang, Xiangsheng Zuo, Anirban Maitra, Robert S. Bresalier

    KRAS mutations drive oncogenic alterations in numerous cancers, particularly in human pancreatic ductal adenocarcinoma (PDAC). About 93% of PDACs have KRAS mutations, with G12D (∼42% of cases) and G12V (∼32% of cases) being the most common. The recent approval of sotorasib (AMG510), a small-molecule, covalent, and selective KRASG12C inhibitor, for treating patients with non–small cell lung cancer represents a breakthrough in KRAS targeted therapy. However, there is a need to develop other much-needed KRAS-mutant inhibitors for PDAC therapy. Notably, Mirati Therapeutics recently developed MRTX1133, a small-molecule, noncovalent, and selective KRASG12D inhibitor through extensive structure-based drug design. MRTX1133 has demonstrated potent in vitro and in vivo antitumor efficacy against KRASG12D-mutant cancer cells, especially in PDAC, leading to its recent initiation of a phase I/II clinical trial. Here, we provide a summary of the recent advancements related to the use of MRTX1133 for treating KRASG12D-mutant PDAC, focusing on its efficacy and underlying mechanistic actions. In addition, we discuss potential challenges and future directions for MRTX1133 therapy for PDAC, including overcoming intrinsic and acquired drug resistance, developing effective combination therapies, and improving MRTX1133’s oral bioavailability and target spectrum. The promising results obtained from preclinical studies suggest that MRTX1133 could revolutionize the treatment of PDAC, bringing about a paradigm shift in its management.


  • Open Access

    PPARδ dysregulation of CCL20/CCR6 axis promotes gastric adenocarcinoma carcinogenesis by remodeling gastric tumor microenvironment

    by Yi Liu, Daoyan Wei, Yasunori Deguchi, Weiguo Xu, Rui Tian, Fuyao Liu, Min Xu, Fei Mao, Donghui Li, Weidong Chen, et al.

    Background: Peroxisome proliferator-activated receptor delta (PPARδ) promotes inflammation and carcinogenesis in many organs, but the underlying mechanisms remains elusive. In stomachs, PPARδ significantly increases chemokine Ccl20 expression in gastric epithelial cells while inducing gastric adenocarcinoma (GAC). CCR6 is the sole receptor of CCL20. Here, we examine the role of PPARδ–mediated Ccl20/Ccr6 signaling in GAC carcinogenesis and investigate the underlying mechanisms. Methods: The effects of PPARδ inhibition by its specific antagonist GSK3787 on GAC were examined in the mice with villin-promoter–driven PPARδ overexpression (PpardTG). RNAscope Duplex Assays were used to measure Ccl20 and Ccr6 levels in stomachs and spleens. Subsets of stomach-infiltrating immune cells were measured via flow cytometry or immunostaining in PpardTG mice fed GSK3787 or control diet. A panel of 13 optimized proinflammatory chemokines in mouse sera were quantified by an enzyme-linked immunosorbent assay. Results: GSK3787 significantly suppressed GAC carcinogenesis in PpardTG mice. PPARδ increased Ccl20 level to chemoattract Ccr6+ immunosuppressive cells, including tumor-associated macrophages, myeloid-derived suppressor cells and T regulatory cells, but decreased CD8+ T cells in gastric tissues. GSK3787 suppressed PPARδ–induced gastric immunosuppression by inhibiting Ccl20/Ccr6 axis. Furthermore, Ccl20 protein levels increased in sera of PpardTG mice starting at the age preceding gastric tumor development and further increased with GAC progression as the mice aged. GSK3787 decreased the PPARδ-upregulated Ccl20 levels in sera of the mice. Conclusions: PPARδ dysregulation of Ccl20/Ccr6 axis promotes GAC carcinogenesis by remodeling gastric tumor microenvironment. CCL20 might be a potential biomarker for the early detection and progression of GAC.


  • Open Access

    Hematopoietic progenitor kinase 1 inhibits the development and progression of pancreatic intraepithelial neoplasia

    by Hua Wang, Rohan Moniruzzaman, Lei Li, Baoan Ji, Yi Liu, Xiangsheng Zuo, Reza Abbasgholizadeh, Jun Zhao, Guangchao Liu, Ruiqi Wang, et al.

    Ras plays an essential role in the development of acinar-to-ductal metaplasia (ADM) and pancreatic ductal adenocarcinoma (PDAC). However, mutant Kras is an inefficient driver for PDAC development. The mechanisms of the switching from low Ras activity to high Ras activity that are required for development and progression of pancreatic intraepithelial neoplasias (PanINs) are unclear. In this study, we found that hematopoietic progenitor kinase 1 (HPK1) was upregulated during pancreatic injury and ADM. HPK1 interacted with the SH3 domain and phosphorylated Ras GTPase-activating protein (RasGAP) and upregulated RasGAP activity. Using transgenic mouse models of HPK1 or M46, a kinase-dead mutant of HPK1, we showed that HPK1 inhibited Ras activity and its downstream signaling and regulated acinar cell plasticity. M46 promoted the development of ADM and PanINs. Expression of M46 in KrasG12D Bac mice promoted the infiltration of myeloid-derived suppressor cells and macrophages, inhibited the infiltration of T cells, and accelerated the progression of PanINs to invasive and metastatic PDAC, while HPK1 attenuated mutant Kras–driven PanIN progression. Our results showed that HPK1 plays an important role in ADM and the progression of PanINs by regulating Ras signaling. Loss of HPK1 kinase activity promotes an immunosuppressive tumor microenvironment and accelerates the progression of PanINs to PDAC.


  • Open Access

    Supplementary Figure 1 from Mechanistic Contribution of Ubiquitous 15-Lipoxygenase-1 Expression Loss in Cancer Cells to Terminal Cell Differentiation Evasion

    by Micheline J. Moussalli, Yuanqing Wu, Xiangsheng Zuo, Xiu L. Yang, Ignacio Ivan Wistuba, Maria G. Raso, Jeffrey S. Morris, Jessica L. Bowser, John D. Minna, Reuben Lotan, et al.